SMN1 and cancer: Despite of a significant reduction in overall dosage in the BAY-I cohort (1440 mg/Kg total dose for BAY-I vs. 2100 mg/kg total dose for BAY-D), both BAY-D and BAY-I showed equal potency in decreasing cancer cell burden after 4 weeks of treatment (Fig. 2A, B right panel) without significant change the pathological features associated with Pten-null CRPC, including nuclear atypia, loss or partially loss of CK5 basal cells and SMA staining and immune cell infiltration (Fig. 2C and Supplementary Figs. 3D and  4A).